Telix Pharmaceuticals Completes Patient Enrollment for Phase 3 Study of Imaging Agents in Prostate Cancer

06:03 AM EDT, 09/02/2026 (MT Newswires) -- Telix Pharmaceuticals (TLX) has completed patient enrollment for the phase 3 study of its commercial PSMA-PET imaging agents Illuccix and Gozellix in prostate cancer imaging in pre-biopsy setting, the company said Wednesday. The company enrolled 350 patients for the study, which will evaluate whether the combination of PSMA-PET/CT and magnetic resonance imaging with Telix's imaging agents will deliver results than current standard practice. Telix said it has aligned with the US Food and Drug Administration on a new drug application pathway for the agents that, once approved, will allow for product reimbursements and expanded patient access.